title: Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.
abstract: In a previous study we showed that multiple deletions of the adenoviral regulatory E1/E3/E4 or E1/E3/E2A genes did not influence the in vivo persistence of the viral genome or affect the antiviral host immune response (Lusky et al., J. Virol. 72:2022-2032, 1998). In this study, the influence of the adenoviral E4 region on the strength and persistence of transgene expression was evaluated by using as a model system the human cystic fibrosis transmembrane conductance regulator (CFTR) cDNA transcribed from the cytomegalovirus (CMV) promoter. We show that the viral E4 region is indispensable for persistent expression from the CMV promoter in vitro and in vivo, with, however, a tissue-specific modulation of E4 function(s). In the liver, E4 open reading frame 3 (ORF3) was necessary and sufficient to establish and maintain CFTR expression. In addition, the E4 ORF3-dependent activation of transgene expression was enhanced in the presence of either E4 ORF4 or E4 ORF6 and ORF6/7. In the lung, establishment of transgene expression was independent of the E4 gene products but maintenance of stable transgene expression required E4 ORF3 together with either E4 ORF4 or E4 ORF6 and ORF6/7. Nuclear run-on experiments showed that initiation of transcription from the CMV promoter was severely reduced in the absence of E4 functions but could be partially restored in the presence of either ORF3 and ORF4 or ORFs 1 through 4. These results imply a direct involvement of some of the E4-encoded proteins in the transcriptional regulation of heterologous transgenes. We also report that C57BL/6 mice are immunologically weakly responsive to the human CFTR protein. This observation implies that such mice may constitute attractive hosts for the in vivo evaluation of vectors for cystic fibrosis gene therapy.
authors.affiliation: TRANSGENE S.A., 67085 Strasbourg, France.
authors.forename: M
authors.initials: M
authors.lastname: Lusky
authors.forename: L
authors.initials: L
authors.lastname: Grave
authors.forename: A
authors.initials: A
authors.lastname: Dieterlé
authors.forename: D
authors.initials: D
authors.lastname: Dreyer
authors.forename: M
authors.initials: M
authors.lastname: Christ
authors.forename: C
authors.initials: C
authors.lastname: Ziller
authors.forename: P
authors.initials: P
authors.lastname: Furstenberger
authors.forename: J
authors.initials: J
authors.lastname: Kintz
authors.forename: D A
authors.initials: DA
authors.lastname: Hadji
authors.forename: A
authors.initials: A
authors.lastname: Pavirani
authors.forename: M
authors.initials: M
authors.lastname: Mehtali
mesh_terms: D000256:Adenoviridae; D017504:Adenovirus E4 Proteins / Q000235:genetics*; D000818:Animals; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D011401:Promoter Regions, Genetic; D014158:Transcription, Genetic
chemical_list: D017504:Adenovirus E4 Proteins; C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator